These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 28099809)

  • 1. Gemcitabine Based Peptide Conjugate with Improved Metabolic Properties and Dual Mode of Efficacy.
    Karampelas T; Skavatsou E; Argyros O; Fokas D; Tamvakopoulos C
    Mol Pharm; 2017 Mar; 14(3):674-685. PubMed ID: 28099809
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GnRH-Gemcitabine conjugates for the treatment of androgen-independent prostate cancer: pharmacokinetic enhancements combined with targeted drug delivery.
    Karampelas T; Argyros O; Sayyad N; Spyridaki K; Pappas C; Morgan K; Kolios G; Millar RP; Liapakis G; Tzakos AG; Fokas D; Tamvakopoulos C
    Bioconjug Chem; 2014 Apr; 25(4):813-23. PubMed ID: 24661240
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable "click" oxime bond tethers and preclinical evaluation against prostate cancer.
    Vrettos EI; Karampelas T; Sayyad N; Kougioumtzi A; Syed N; Crook T; Murphy C; Tamvakopoulos C; Tzakos AG
    Eur J Med Chem; 2021 Feb; 211():113018. PubMed ID: 33223264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of bioactive gemcitabine-D-Lys
    Sayyad N; Vrettos EI; Karampelas T; Chatzigiannis CM; Spyridaki K; Liapakis G; Tamvakopoulos C; Tzakos AG
    Eur J Med Chem; 2019 Mar; 166():256-266. PubMed ID: 30716713
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro.
    Grégoire V; Rosier JF; De Bast M; Bruniaux M; De Coster B; Octave-Prignot M; Scalliet P
    Radiother Oncol; 2002 Jun; 63(3):329-38. PubMed ID: 12142097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The deaminated metabolite of gemcitabine, 2',2'-difluorodeoxyuridine, modulates the rate of gemcitabine transport and intracellular phosphorylation via deoxycytidine kinase.
    Hodge LS; Taub ME; Tracy TS
    Drug Metab Dispos; 2011 Nov; 39(11):2013-6. PubMed ID: 21832002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Docetaxel-resistant prostate cancer cells become sensitive to gemcitabine due to the upregulation of ABCB1.
    Seo HK; Lee SJ; Kwon WA; Jeong KC
    Prostate; 2020 May; 80(6):453-462. PubMed ID: 32134535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gonadotropin-Releasing Hormone Receptors in Prostate Cancer: Molecular Aspects and Biological Functions.
    Fontana F; Marzagalli M; Montagnani Marelli M; Raimondi M; Moretti RM; Limonta P
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33327545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peptide-Drug Conjugate GnRH-Sunitinib Targets Angiogenesis Selectively at the Site of Action to Inhibit Tumor Growth.
    Argyros O; Karampelas T; Asvos X; Varela A; Sayyad N; Papakyriakou A; Davos CH; Tzakos AG; Fokas D; Tamvakopoulos C
    Cancer Res; 2016 Mar; 76(5):1181-92. PubMed ID: 26645560
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological factors affecting accumulation of gemcitabine's active metabolite, gemcitabine triphosphate.
    Rizzuto I; Ghazaly E; Peters GJ
    Pharmacogenomics; 2017 Jun; 18(9):911-925. PubMed ID: 28594276
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor.
    Montagnani Marelli M; Manea M; Moretti RM; Marzagalli M; Limonta P
    Int J Oncol; 2015 Jan; 46(1):243-53. PubMed ID: 25351635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maspin mediates the gemcitabine sensitivity of hormone-independent prostate cancer.
    Huang CY; Chang YJ; Luo SD; Uyanga B; Lin FY; Tai CJ; Huang MT
    Tumour Biol; 2016 Mar; 37(3):4075-82. PubMed ID: 26490978
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro and in vivo evaluation of 64Cu-labeled SarAr-bombesin analogs in gastrin-releasing peptide receptor-expressing prostate cancer.
    Lears KA; Ferdani R; Liang K; Zheleznyak A; Andrews R; Sherman CD; Achilefu S; Anderson CJ; Rogers BE
    J Nucl Med; 2011 Mar; 52(3):470-7. PubMed ID: 21321264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
    Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
    Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous determination of gemcitabine prodrug, gemcitabine and its major metabolite 2', 2'-difluorodeoxyuridine in rat plasma by UFLC-MS/MS.
    Sun Y; Zhen L; Peng Y; Wang J; Fei F; Aa L; Jiang W; Pei X; Lu L; Liu J; Wang G; Hao K
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 May; 1084():4-13. PubMed ID: 29558739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties.
    Hong S; Fang Z; Jung HY; Yoon JH; Hong SS; Maeng HJ
    Molecules; 2018 Oct; 23(10):. PubMed ID: 30314360
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Antitumor Activity of Monophosphate Ester Prodrugs of Gemcitabine: In Vitro and In Vivo Evaluation.
    Qi H; Lu J; Li J; Wang M; Xu Y; Wang Y; Zhang H
    J Pharm Sci; 2016 Sep; 105(9):2966-2973. PubMed ID: 26994559
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enzyme-responsive peptide dendrimer-gemcitabine conjugate as a controlled-release drug delivery vehicle with enhanced antitumor efficacy.
    Zhang C; Pan D; Li J; Hu J; Bains A; Guys N; Zhu H; Li X; Luo K; Gong Q; Gu Z
    Acta Biomater; 2017 Jun; 55():153-162. PubMed ID: 28259838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acid-Triggered Release of Native Gemcitabine Conjugated in Polyketal Nanoparticles for Enhanced Anticancer Therapy.
    Zhong H; Mu J; Du Y; Xu Z; Xu Y; Yu N; Zhang S; Guo S
    Biomacromolecules; 2020 Feb; 21(2):803-814. PubMed ID: 31995366
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine: a critical nucleoside for cancer therapy.
    Gesto DS; Cerqueira NM; Fernandes PA; Ramos MJ
    Curr Med Chem; 2012; 19(7):1076-87. PubMed ID: 22257063
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.